Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic effcacy of docetaxel-loaded poly(ethylene glycol)-poly(ε-caprolactone) nanoparticles

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 281-295

  Liu, Qin ^a   Li, Ru Tian ^a   Qian, Han Qing ^b   Yang, Mi ^a   Zhu, Zhen Shu ^b   Wu, Wei ^b   Qian, Xiao Ping ^a   Yu, Li Xia ^a   Jiang, Xi Qun ^b   Liu, Bao Rui ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Antitumor; Docetaxel; Drug delivery; Gelatinase; Stimuli responsive

Indexed keywords

DOCETAXEL; GELATINASE; MACROGOL; NANOPARTICLE; POLYCAPROLACTONE; POLY(ETHYLENE GLYCOL) POLY(EPSILON CAPROLACTONE) NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOMA; LUNG CARCINOMA; MOUSE; NONHUMAN; SYNTHESIS; CARCINOMA CELL; CELL TRANSPORT; COLON CANCER; MALE; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYMERIZATION; TUMOR VOLUME;

ABSORBABLE IMPLANTS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; CARCINOMA, LEWIS LUNG; COLONIC NEOPLASMS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GELATINASES; HUMANS; INJECTIONS, INTRAVENOUS; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED ICR; NANOPARTICLES; PARTICLE SIZE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RANDOM ALLOCATION; TAXOIDS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 84863012121     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S26697     Document Type: Article

References (43)

1. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103(16):6315-6320.
2. Liu Z, Cai W, He L, et al. In vivo biodistribution and highly effcient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol. 2007;2(1):47-52.
3. Li LY, Wartchow CA, Danthi SN, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-FLK-1 antibody coated Y-90-labeled nanoparticles. Int J Radiat Oncol. 2004;58(4):1215-1227.
4. Werner ME, Karve S, Sukumar R, et al. Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials. 2011;32(33):8548-8554.
5. Tai W Y, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264-275.
6. Dai S, Ravi P, Tam KC. Thermo- and photo-responsive polymeric systems. Soft Matter. 2009;5(13):2513-2533.
7. Chen B, Cheng J, Wu Y, et al. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice. Int J Nanomedicine. 2009; 4:73-78.
8. Konno T, Hasuda H, Ishihara K, Ito Y. Photo-immobilization of a phospholipid polymer for surface modifcation. Biomaterials. 2005; 26(12):1381-1388.
9. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135-146.
10. Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nature Clinical Practice Oncology. 2008;5(4):206-219.
11. Law B, Tung CH. Proteolysis: A biological process adapted in drug delivery, therapy, and imaging. Bioconjugate Chem. 2009;20(9): 1683-1695.
12. Zhu L, Xie J, Swierczewska M, et al. Real-time video imaging of protease expression in vivo. Theranostics. 2011;1:18-27.
13. Davidsen J, Vermehren C, Frokjaer S, Mouritsen OG, Jorgensen K. Drug delivery by phospholipase A(2) degradable liposomes. Int J Pharm. 2001;214(1-2):67-69.
14. Aimetti AA, Tibbitt M W, Anseth KS. Human neutrophil elastase responsive delivery from poly(ethylene glycol) hydrogels. Biomacromolecules. 2009;10(6):1484-1489.
15. Kessenbrock K, Plaks V, Werb Z. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell. 2010;141(1):52-67.
16. Lopez-Otin C, Matrisian LM. Tumour micro environment-opinion-emerging roles of proteases in tumour suppression. Nat Rev Cancer. 2007;7(10):800-808.
17. Gupta G P, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679-695.
18. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27(31):5287-5297.
19. Albright CF, Graciani N, Han W, et al. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Mol Cancer Ther. 2005;4(5): 751-760.
20. Terada T, Iwai M, Kawakami S, et al. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J Control Release. 2006;111(3):333-342.
21. Elegbede AI, Banerjee J, Hanson AJ, et al. Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9. J Am Chem Soc. 2008;130(32):10633-10642.
22. Li RT, Li XL, Xie L, et al. Preparation and evaluation of PEG-PCL nanoparticles for local tetradrine delivery. Int J Pharm. 2009;379(1): 158-166.
23. Zhu ZS, Li Y, Li XL, et al. Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo. J Control Release. 2010;142(3):438-446.
24. Cho Y W, Lee J, Lee SC, Huh KM, Park K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J Control Release. 2004;97(2):249-257.
25. Hu Y, Xie J, Tong Y W, Wang CH. Effect of PEG conformation and particle size on the cellular uptake effciency of nanoparticles with the HepG2 cells. J Control Release. 2007;118(1):7-17.
26. Fingleton B. MMPs as therapeutic targets - Still a viable option? Semin Cell Dev Biol. 2008;19(1):61-68.
27. Overall CM, Kleifeld O. Towards third generation matrix metallo-proteinase inhibitors for cancer therapy. Brit J Cancer. 2006;94(7): 941-946.
28. Joralemon MJ, Mcrae S, Emrick T. PEGylated polymers for medicine: from conjugation to self-assembled systems. Chem Commun. 2010; 46(9):1377-1393.
29. Wu W, Li RT, Bian XC, et al. Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity. Acs Nano. 2009;3(9):2740-2750.
30. Karakoti AS, Das S, Thevuthasan S, Seal S. PEGylated inorganic nanoparticles. Angew Chem Int Edit. 2011;50(9):1980-1994.
31. Walker GF, Fella C, Pelisek J, et al. Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol Ther. 2005;11(3):418-425.
32. Lee S, Ryu JH, Park K, et al. Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination in vivo. Nano Lett. 2009;9(12):4412-4416.
33. Turk BE, Huang LL, Piro ET, Cantley LC. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol. 2001;19(7):661-667.
34. Hatakeyama H, Ito E, Akita H, et al. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J Control Release. 2009;139(2):127-132.
35. Hatakeyama H, Akita H, Kogure K, et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specifc cleavable PEG-lipid. Gene Ther. 2007;14(1):68-77.
36. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615-627.
37. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188(6):759-768.
38. Nagano S, Perentes J Y, Jain RK, Boucher Y. Cancer cell death enhances the penetration and effcacy of oncolytic herpes simplex virus in tumors. Cancer Res. 2008;68(10):3795-3802.
39. Goodman TT, Olive PL, Pun SH. Increased nanoparticle penetration in collagenase-treated multicellular spheroids. Int J Nanomedicine. 2007; 2(2):265-274.
40. Mizushima T, Ishihara T, Takeda M, et al. Accelerated blood clearance phenomenon upon repeated injection of PEG-modifed PLA-nanoparticles. Pharmaceut Res. 2009;26(10):2270-2279.
41. Park K. To PEGylate or not to PEGylate, that is not the question. J Control Release. 2010;142(2):147-148.
42. Chen D, Liu W, Shen Y, Mu H, Zhang Y, Liang R, et al. Effects of a novel pH-sensitive liposome with cleavable esterase-catalyzed and pH-responsive double smart mPEG lipid derivative on ABC phenomenon. Int J Nanomedicine. 2011;6:2053-2061.
43. Xu H, Wang KQ, Chen DW, Deng YH. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials. 2010;31(17):4757-4763.